PD-1 Immunotherapy Plus Adjuvants Shows Promise in Metastatic Breast Cancer Case

While PD-1 inhibitors (immune checkpoint blockade) have revolutionized cancer treatment, their efficacy in advanced metastatic breast cancer can be limited, particularly in "cold" tumors with low immune cell infiltration. This often leads to immune evasion and resistance to conventional therapies, presenting a significant challenge. There is a critical need to explore combination strategies that can enhance anti-tumor immunity and improve patient outcomes in this difficult-to-treat population.

The patient demonstrated a remarkable and sustained clinical response to the combination therapy. Imaging revealed a partial response with a 55% reduction in the target lesion size by month 3, which was maintained for over 10 months. Circulating tumor DNA (ctDNA) levels, a marker of tumor burden, decreased by 80% from baseline within 2 months of initiating treatment. Immunological analysis showed a 2.3-fold increase in peripheral CD8+ T cells (cytotoxic T lymphocytes) and a 1.8-fold increase in the CD8+/Treg ratio, indicating enhanced anti-tumor immunity. The most significant finding was the sustained partial remission in a patient with PD-L1-negative metastatic breast cancer, a subtype typically less responsive to PD-1 monotherapy, suggesting a synergistic effect of the combined regimen.